Lista de obras -

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

artículo científico publicado en 2004

A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.

artículo científico publicado en 2005

A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.

artículo científico publicado en 2008

A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients

artículo científico publicado en 2002

A prospective evaluation of rectal bleeding after dose-escalated three-dimensional conformal radiation therapy using an intrarectal balloon for prostate gland localization and immobilization

scientific article published on 11 April 2006

Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population

artículo científico publicado en 2004

Acupuncture as palliative therapy for physical symptoms and quality of life for advanced cancer patients

artículo científico publicado en 2010

Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesis

artículo científico publicado en 2004

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy

artículo científico publicado en 2006

Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer

scientific article published on 01 July 2002

Development of an integrated prostate cancer research information system.

artículo científico publicado en 2006

Effects of complementary therapies on clinical outcomes in patients being treated with radiation therapy for prostate cancer

artículo científico publicado en 2010

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up

artículo científico publicado en 2003

Gene expression correlates of clinical prostate cancer behavior

article

Lack of radiation dose response for patients with low-risk clinically localized prostate cancer: a retrospective analysis

scientific article published on 01 August 2002

Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancer

artículo científico publicado en 2003

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

artículo científico publicado en 2005

Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity

artículo científico publicado en 2003

Patient-reported acute gastrointestinal toxicity in men receiving 3-dimensional conformal radiation therapy for prostate cancer with or without neoadjuvant androgen suppression therapy

artículo científico publicado en 2005

Phase II Study of Low Dose and High Dose Conjugated Estrogen for Androgen Independent Prostate Cancer

article

Phase III study of ibuprofen versus placebo for radiation-induced genitourinary side effects

artículo científico publicado en 2002

Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy

artículo científico publicado en 2005

Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer

artículo científico publicado en 2004

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results

artículo científico publicado en 2018

Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes

artículo científico publicado en 2006

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy

artículo científico publicado en 2004

Selective aromatase inhibition for patients with androgen-independent prostate carcinoma

artículo científico publicado en 2002

TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

artículo científico publicado en 2007

The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins

artículo científico publicado en 2009

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

artículo científico publicado en 2004

Lista de obras de

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.

A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.

A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients

A prospective evaluation of rectal bleeding after dose-escalated three-dimensional conformal radiation therapy using an intrarectal balloon for prostate gland localization and immobilization

Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population

Acupuncture as palliative therapy for physical symptoms and quality of life for advanced cancer patients

Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesis

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy

Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer

Development of an integrated prostate cancer research information system.

Effects of complementary therapies on clinical outcomes in patients being treated with radiation therapy for prostate cancer

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up

Gene expression correlates of clinical prostate cancer behavior

Lack of radiation dose response for patients with low-risk clinically localized prostate cancer: a retrospective analysis

Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancer

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity

Patient-reported acute gastrointestinal toxicity in men receiving 3-dimensional conformal radiation therapy for prostate cancer with or without neoadjuvant androgen suppression therapy

Phase II Study of Low Dose and High Dose Conjugated Estrogen for Androgen Independent Prostate Cancer

Phase III study of ibuprofen versus placebo for radiation-induced genitourinary side effects

Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy

Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results

Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy

Selective aromatase inhibition for patients with androgen-independent prostate carcinoma

TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways